Houston healthtech leader launches clinical trial for innovative anxiety-treating device

making waves

Nexalin Technology is launching a Phase II clinical trial of its neurostimulation device for adult patients suffering from anxiety and insomnia. File image.

Houston-based Nexalin Technology’s proprietary neurostimulation device will move forward with a new clinical trial evaluating its treatment of anxiety disorders and chronic insomnia in Brazil.

The first of Nexalin’s Gen-2 15-milliamp neurostimulation devices have been shipped to São Paulo, Brazil, and the study will be conducted at the Instituto de Psiquiatria university hospital (IPq-HCFMUSP). The shipments aim to support the launch of a Phase II clinical trial in adult patients suffering from anxiety and insomnia, according to a news release.

“Brazil is an important emerging market for mental health innovation, and this collaboration marks our first IRB-approved study in the region,” Mike White, CEO of Nexalin, said in the release.

The study will be led by Dr. Andre Russowsky Brunoni, who specializes in neuromodulation and interventional psychiatry. He currently serves as director of the interventional psychiatry division at IPq-HCFMUSP and this summer will join UT Southwestern in Dallas and its Peter O’Donnell Jr. Brain Institute as a professor of psychiatry.

The Phase II study plans to enroll 30 adults in São Paulo and assess the efficacy of Nexalin’s non-invasive deep intracranial frequency stimulation (DIFS™) of the brain in reducing anxiety symptoms and improving sleep quality, according to the company. Using the Hamilton Anxiety Rating Scale (HAM-A), the trial’s goal is a reduction in anxiety symptoms, and assessments of sleep onset latency, total sleep time, overall sleep quality, depressive symptoms and clinical impression of improvement. The company plans to share results in a peer-reviewed scientific journal.

“Anxiety and insomnia are very common conditions that often occur together and cause significant distress,” Brunoni added in the news release. “In this study, we are testing a new, non-invasive brain stimulation technology that has shown promising results in recent research. Our goal is to offer a safe, painless, and accessible alternative to improve people’s well being and sleep quality.”

The Nexalin Gen-2 15-milliamp neurostimulation device has been approved in China, Brazil, and Oman.

The company also enrolled the first patients in its clinical trial at the University of California, San Diego, in collaboration with the VA San Diego Healthcare System for its Nexalin HALO, which looks to treat mild traumatic brain injury and post-traumatic stress disorder in military personnel and the civilian population. It also recently raised $5 million through a public stock offering. Read more here.

From Your Site Articles
A new medical device created in Houston is revolutionizing opioid withdrawal treatment. Photo via sparkbiomedical.com

Houston med-tech companies partner on wearable device for opioid withdrawal

treating addiction

Houston-based Spark Biomedical has created a revolutionary wearable device that provides unprecedented levels of opioid withdrawal relief.

The device known as the Sparrow Therapy System is worn over the ear for five to seven days and sends mild electrical signals to trigger cranial nerves that sit near the skin's surface.

Once activated, the nerves release endorphins that the body has stopped producing on its own during opioid use. The endorphins satisfy the opioid receptors and in turn reduce or prevent the intense symptoms that often come along with opioid withdrawal. According to Spark BioMed CEO Daniel Powell, the technology also helps patients better control their "flight or fight mechanisms," allowing them to make clearer, more logical decisions as they come off of the drug.

"If you ask 100 people who've gone through opioid withdrawal, I would bet 99 of them will tell you they thought they were going to die," Powell says. "Giving them the ability to manage that is huge. It's the first step towards addiction recovery. It's not solving the addiction, but it is an absolute barrier to move forward."

The product was approved by the FDA in January of 2020, after clinical trials showed that the Sparrow could meaningfully reduce withdrawal symptoms in the first hour of use. According to Powell, roughly a third of patients in the trial were completely out of withdrawal and patients' Clinical Opioid Withdrawal Scales scores reduced by more than 53 percent across the board.

Spark, which won Venture Houston's inaugural pitch competition earlier this year, partnered with Houston-based Velentium (which also happened to grow 93 percent last year after partnering with General Motors on Project V) to bring the product from concept to commercial physician prescribed product. "We needed a more sophisticated design house to help us finish it," Powell says.

The up-and-comers were connected through one of Spark's investors. Powell, in a previous career, had also sold a neurostimulator that Velentium CTO Randy Armstrong had invented.

"You're seeing more and more Houston centric medical innovation than we've ever seen before," says Velentium CEO Dan Purvis. "And the cool thing about that is there ends up being a camaraderie amongst entrepreneurs, medical researchers and scientists."

And though the release of Sparrow marks a huge milestone, neither Spark of Velentium are stopping there. Moving forward, Spark aims to conduct a massive study on how a similar technology, dubbed the Roo, can aid infants born to opioid-dependent mothers wean from the drug.

The company also aims to create a next generation Sparrow with the help of Velentium, and will look at long-term uses of the product. Powell says that Spark will look to determine if the product can prevent relapses and help to cure addiction when worn daily or regularly.

"Our big, crazy, ambitious goal is can we actually help people recover from addiction," Powell says. "We're really not addressing psychology, that's going to be in cognitive behavioral therapy. But if we can remove the neurological results of drug use, we think we can make at least start to stack the deck in the favor of the patient versus having the deck stacked completely against them all the time."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

  • No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
  • No. 2 for emerging regions for jobs, with 28,000 jobs
  • No. 2 for lab space, with roughly 8 million square feet in the market
  • No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

  • No. 2 Minneapolis-St. Paul
  • No. 3 Denver-Boulder
  • No. 4 St. Louis
  • No. 5 Dallas-Fort Worth

States to make the list include:

  • No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
  • No. 2 Indiana (including Indianapolis)
  • No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
  • No. 4 Georgia (including Atlanta and Augusta)
  • No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

  • Phoenix
  • Pittsburgh
  • Greater Richmond, Virginia
  • South Carolina
  • Utah

See the full report here.

Major Texas-based airlines ground humanoid robots as passengers

In The Air

Two major airlines based in Texas are drawing a hard line between human and humanoid: American Airlines and Southwest Airlines won’t permit human-like or animal-like robots to board flights as passengers.

Fort Worth-based American and Dallas-based Southwest recently adopted bans on robotic passengers after two incidents in which human-like robots joined flesh-and-blood passengers on Southwest flights.

In May, Aaron Mehdizadeh, owner of The Robot Studio rental company in Dallas, was heading from Las Vegas to Dallas Love Field with 3.5-foot-tall Stewie, according to CBS News Texas. Rather than shipping Stewie as cargo, Mehdizadeh bought the robot its own seat using a type of ticket often purchased for fragile items such as wedding dresses and equipment.

But because Stewie was technically a carry-on item, the robot wasn’t supposed to occupy a seat, according to eWeek. Crew members wound up disconnecting Stewie’s battery and relocating the robot to a window seat before takeoff.

Mehdizadeh pushed back on Southwest’s stance regarding the battery, telling CBS News Texas that Stewie’s power supply is a standard battery that’s similar to one for a laptop.

Stewie isn’t the only robot making mischief in the skies. In May, a 70-pound, human-like robot named Bebop caused a stir on a Southwest flight from Oakland, California, to San Diego.

The robot prompted a nearly one-hour flight delay after crew members realized it violated restrictions on large carry-ons and raised concerns about the battery, San Francisco TV station KGO reported. Dallas-based Elite Event Robotics owns Bebop.

Southwest seized Bebop’s lithium-ion battery, but the airline did let Bebop take the San Diego-bound flight.

Southwest’s new robot policy prohibits human-like or animal-like robots from riding in an airplane cabin or as checked baggage, no matter their size or purpose. All other robots, including toys, must fit in a carry-on size bag and comply with battery restrictions, the airline says.

In a statement sent to CultureMap, a Southwest spokeswoman says the airline “has taken a strong stance on this issue and has led the U.S. airline industry with our battery policy.”

“The robot policy is a further evolution of a [safety] journey we have been on for several months. This move was not in response to any single incident,” the spokeswoman adds. “To eliminate confusion, the policy applies to all similar devices, regardless of size.”

Lithium-ion batteries can overheat, catch on fire, or explode on airplanes.

American’s new robot policy, which took effect Monday, August 17, is similar to Southwest’s. The policy prohibits human-like and animal-like robots from sitting in a purchased seat, being stored in an overhead bin or traveling as checked baggage. The ban applies to U.S., international, and regional flights.

“While there have been no known events involving this type of robot on any American flight, this policy was developed following a comprehensive review of safety risks associated with these devices, including the large lithium-ion batteries that power them,” the airline said in an internal memo obtained by the View From the Wing travel blog.

American gate agents have been told not to allow a passenger accompanied by a robot to board a plane or to let a robot travel as a checked item, the memo say.

If a robot is discovered after check-in, American employees are supposed to follow the Federal Aviation Administration’s “undeclared dangerous goods” procedures. These procedures cover hazardous shipments like lithium-ion batteries, explosives, flammable liquids, and compressed gases that lack required warning labels or shipping documents.

---

This article originally appeared on CultureMap.com.

Texas A&M, UH rise in global rankings of universities attracting the most attention

visibility report

Houston and Texas universities had a strong showing on the 2026-27 Global University Visibility (GUV) Rankings compiled by D.C.-based higher ed market research firm American Caldwell.

Texas A&M ranked No. 6 on the list—the top rank of any Texas university. Meanwhile, the University of Houston ranked No. 52, a 15-spot jump from its previous ranking.

The GUV rankings rate colleges that garner the most global attention via news coverage, social media influence, website traffic, YouTube views, and general public interest. GUV evaluated over 1,200 universities across 193 United Nations-recognized countries.

Texas A&M, with its No. 6 global ranking, also claimed the No. 5 spot among U.S. institutions. The university climbed 21 spots from its previous rank.

“News mentions were a driver of Texas A&M’s movement in this year’s rankings, and earned media remains one of the strongest signals of relevance,” Tim Doty, associate vice president for earned media at Texas A&M, said in a news release. “Much of that visibility begins with our faculty and research experts, whose work helps explain, solve and give context to issues people care about. When Texas A&M experts appear in news stories about research, discovery, national security, agriculture, health, engineering, service and the future of Texas, audiences see the university not only as large or well known, but as useful, relevant and necessary to the conversations shaping our state and country.”

In the “Public Interest” category, UH also claimed a top 10 global ranking at No.6. UH touts its overall GUV rankings success to Guggenheim Fellowships, MacArthur “Genius” grants, National Academy membership, studies like researchers breaking the superconductivity temperature record, and success on the football field and basketball courts.

“Across the board, there is no question that the University of Houston is a brand on the rise,” Shawn Lindsey, interim vice president for marketing and communications, said in a news release. “People are seeing our story, hearing about the amazing things happening at UH and actively seeking us out to learn more. We are seeing it in record-high student applications, we are seeing increases in trademark licensing revenue, our faculty are earning global accolades. It’s an exciting time to be a Houston Cougar.”

Other Texas institutions to make the top 250 on the list include:

  • No. 22 The University of Texas at Austin
  • No. 104 University of Texas at Dallas
  • No. 159 Texas Tech University
  • No. 178 Rice University
  • No. 191 University of North Texas
  • No. 248 Texas State University

For the fourth year in a row, Harvard University secured the top spot on the list, followed by MIT, Stanford University and Purdue University. The University of Oxford was the top non-U.S. institution at No. 5.

See the full list here.

View All Listings